微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 81.2% | 1.76% | -1.03% | 18/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 82.05% | 0.44% | -2.44% | 17/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 84.1% | 1.93% | 4.84% | 15/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 80.22% | -1.38% | 0.53% | 21/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 79.8% | -2.48% | -2.31% | 22/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 81.69% | -0.03% | -0.99% | 16/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 82.5% | 0.93% | 1.43% | 14/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 81.34% | 0.66% | -0.59% | 20/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 81.83% | 0.17% | 0.14% | 18/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 81.71% | 1.42% | -0.04% | 18/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 81.75% | 1.56% | 1.16% | 18/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 80.81% | -7.11% | -1.08% | 23/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 81.69% | -7.69% | 1.39% | 19/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 80.57% | -9.69% | 0.1% | 22/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 80.49% | -8.87% | -7.47% | 23/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 86.99% | -4.49% | -1.7% | 11/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 88.49% | -3.81% | -0.81% | 8/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 89.22% | -3.29% | 1.01% | 7/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 88.33% | -5.18% | -3.02% | 9/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 91.08% | -0.75% | -0.99% | 11/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 92% | 1.18% | -0.27% | 7/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 92.25% | 2.45% | -0.97% | 6/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 93.15% | 2.96% | 1.51% | 4/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 91.77% | -0.86% | 0.93% | 6/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 90.93% | -2% | 0.98% | 6/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 90.04% | -2.97% | -0.48% | 5/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 90.48% | -2.68% | -2.25% | 4/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 92.56% | -0.4% | -0.24% | 4/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 92.78% | -0.51% | -0.02% | 3/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 92.8% | -0.69% | -0.18% | 3/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 92.97% | -0.88% | 0.03% | 3/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 92.94% | 0.04% | -0.34% | 3/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 93.25% | 246.8% | -0.2% | 2/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 93.44% | 348.22% | -0.37% | 2/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 93.79% | 263.83% | 0.96% | 2/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 92.9% | 383.17% | 245.47% | 4/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 26.89% | 100.32% | 28.99% | 84/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 20.85% | 1432.26% | -19.13% | 97/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 25.78% | 293.44% | 34.08% | 76/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 19.23% | -41.7% | 43.23% | 108/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 13.42% | -58.71% | 957.83% | 80/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | -1.56% | -105.5% | -123.88% | 89/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 6.55% | -75.73% | -80.13% | 78/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |